Jen-Chieh Tseng

In vivo antitumor activity of Sindbis viral vectors.

Systemic tumor targeting and killing by Sindbis viral vectors.

Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models.

Identification of amino acids of Sindbis virus E2 protein involved in targeting tumor metastases in vivo.

Gene therapy that safely targets and kills tumor cells throughout the body.

Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET.

CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia.

Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy.

Activation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectors.

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo.

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Incongruity of imaging using fluorescent 2-DG conjugates compared to 18F-FDG in preclinical cancer models.

Tumor-specific targeting with modified Sindbis viral vectors: evaluation with optical imaging and positron emission tomography in vivo.

In vivo imaging of inflammatory phagocytes.

In Vivo Fluorescent Labeling of Tumor Cells with the HaloTag® Technology.